OnKure Therapeutics, Inc. (OKUR) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
6707 Winchester Circle
Boulder, CO 80301
United States of America (the)
Phone
720 307 2892
Sector
Healthcare
Industry
Biotechnology
Employees
46
First IPO Date
April 08, 2021
| Name | Title | Pay | Year Born |
| Nicholas A. Saccomano | President, Chief Executive Officer & Director | 858,000 | 1959 |
| Isaac Manke | Senior VP of Business Development & Director | 60,497 | 1977 |
| Jason A. Leverone | Chief Financial Officer | 591,200 | 1974 |
| Samuel Agresta | Chief Medical Officer | 640,600 | 1973 |
| Kevin S. Litwiler | Senior Vice President of DMPK & Clinical Pharmacology | 0 | N/A |
| James Blake | Senior Vice President of Computational Drug Discovery | 0 | N/A |
| Mark L. Boys | Senior Vice President of Discovery Chemistry | 0 | N/A |
| Rogan Nunn | General Counsel & Secretary | 0 | N/A |
| Roberta Alton | Senior Vice President of Clinical Operations | 0 | N/A |
| Dylan Hartley | Chief Scientific Officer | 0 | 1969 |
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.